CONTENT VALIDATION AND DISCLOSURES
Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the Research To Practice scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — Dr Kris had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Perez-Soler — Consulting Fees, Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents and Ownership Interest: Eli Lilly and Company, Genentech BioOncology; Receipt of Intellectual Property Rights/Patent Holder: Hana Biosciences Inc. Dr Brahmer — Consulting Agreements: Cephalon Inc, Eli Lilly and Company, Genentech BioOncology; Paid Research: AstraZeneca Pharmaceuticals LP, Medarex Inc, Merck and Company Inc, Pfizer Inc, Wyeth. Dr Bonomi — Advisory Committee: Eli Lilly and Company, ImClone Systems Incorporated, OSI Pharmaceuticals Inc; Consulting Agreement and Speakers Bureau: Eli Lilly and Company; Paid Research: Eli Lilly and Company, Genentech BioOncology, GlaxoSmithKline, ImClone Systems Incorporated, Novartis Pharmaceuticals Corporation, OSI Pharmaceuticals Inc, Pfizer Inc.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
Table of Contents | Top of Page |
EDITOR
Neil Love, MD
INTERVIEWS
Mark G Kris, MD
- Select publications
Roman Perez-Soler, MD
- Select publications
Julie R Brahmer, MD
- Select publications
Philip Bonomi, MD
- Select publications
Lung Cancer Update:
A CME Audio Series and Activity